Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01389323 · ClinicalTrials.gov registry record · Phase 3
BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 448
- Enrollment target
NCT01389323 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 448 participants.
The verdict
NCT01389323, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 448 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the rates of sustained virologic response in each cohort (Black-African Americans, Latinos) in this study to historical rate.
Interventions
- DRUG Ribavirin
- DRUG Daclatasvir
- DRUG Peg-Interferon Alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 448 participants |
| Start Date | 2011-09 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01389323
The ClinicalTrials.gov registry entry for NCT01389323 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 448 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT01389323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01389323 about?
NCT01389323 is a clinical study titled "BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C". The purpose of this study is to compare the rates of sustained virologic response in each cohort (Black-African Americans, Latinos) in this study to historical rate.
What is the current status of trial NCT01389323?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 448 participants. The study started on 2011-09. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01389323?
The interventions under investigation include: Ribavirin (DRUG), Daclatasvir (DRUG), Peg-Interferon Alfa-2a (DRUG).
Who is sponsoring clinical trial NCT01389323?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.